Literature DB >> 19680598

Beyond tremor and rigidity: non-motor features of Parkinson's disease.

Matthias Löhle1, Alexander Storch, Heinz Reichmann.   

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease and primarily considered as a movement disorder defined by the presence of motor symptoms, such as bradykinesia, tremor and rigidity. However, it is nowadays widely accepted that PD is associated with a wide variety of non-motor features, which affect the vast majority of patients during the course of the disease and may even precede the onset of motor symptoms. The spectrum of these non-motor disturbances is very broad and comprises neuropsychiatric conditions, such as depression, dementia and hallucinations, as well as autonomic, sensory and sleep disorders. Physicians need to be aware of these non-motor features, since they have substantial impact on the health-related quality of life of PD patients, even ahead of motor symptoms. This article aims to provide an overview of frequently observed non-motor features in PD and discusses prospects and limitations of currently available options for symptomatic treatment of these disturbances.

Entities:  

Mesh:

Year:  2009        PMID: 19680598     DOI: 10.1007/s00702-009-0274-1

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  128 in total

1.  Daytime sleepiness, agonist therapy, and driving in Parkinson disease.

Authors:  Cynthia L Comella
Journal:  JAMA       Date:  2002 Jan 23-30       Impact factor: 56.272

2.  Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.

Authors:  William G Ondo; Ron Tintner; Kevin Dat Voung; Dejian Lai; George Ringholz
Journal:  Mov Disord       Date:  2005-08       Impact factor: 10.338

Review 3.  Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology.

Authors:  L L Edwards; E M Quigley; R F Pfeiffer
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

4.  Mental symptoms in Parkinson's disease are important contributors to caregiver distress.

Authors:  D Aarsland; J P Larsen; K Karlsen; N G Lim; E Tandberg
Journal:  Int J Geriatr Psychiatry       Date:  1999-10       Impact factor: 3.485

5.  Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls.

Authors:  E K Tan; S Y Lum; S M C Fook-Chong; M L Teoh; Y Yih; L Tan; A Tan; M C Wong
Journal:  Neurology       Date:  2002-02-12       Impact factor: 9.910

6.  Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease.

Authors:  Alan Breier; Virginia K Sutton; Peter D Feldman; Deborah L Kadam; Iris Ferchland; Padraig Wright; Joseph H Friedman
Journal:  Biol Psychiatry       Date:  2002-09-01       Impact factor: 13.382

7.  Lewy body dementia and Parkinson's disease with dementia.

Authors:  Richard Dodel; Ilona Csoti; Georg Ebersbach; Gerd Fuchs; Matthias Hahne; Wilfried Kuhn; Matthias Oechsner; Wolfgang Jost; Heinz Reichmann; Jörg B Schulz
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

Review 8.  Rapid eye movement sleep behavior disorder.

Authors:  James J Gugger; Mary L Wagner
Journal:  Ann Pharmacother       Date:  2007-10-09       Impact factor: 3.154

9.  Prevalence of smell loss in Parkinson's disease--a multicenter study.

Authors:  A Haehner; S Boesveldt; H W Berendse; A Mackay-Sim; J Fleischmann; P A Silburn; A N Johnston; G D Mellick; B Herting; H Reichmann; T Hummel
Journal:  Parkinsonism Relat Disord       Date:  2009-01-11       Impact factor: 4.891

10.  Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study.

Authors:  Roberta Zangaglia; Emilia Martignoni; Margaret Glorioso; Maria Ossola; Giulio Riboldazzi; Daniela Calandrella; Gabriele Brunetti; Claudio Pacchetti
Journal:  Mov Disord       Date:  2007-07-15       Impact factor: 10.338

View more
  14 in total

Review 1.  Parkinson's disease dementia.

Authors:  Mary J Docherty; David J Burn
Journal:  Curr Neurol Neurosci Rep       Date:  2010-07       Impact factor: 5.081

Review 2.  Neurological diseases and pain.

Authors:  David Borsook
Journal:  Brain       Date:  2011-11-08       Impact factor: 13.501

3.  Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?

Authors:  Martin Bareš; Irena Rektorová; Robert Jech; Kateřina Farníková; Jan Roth; Evžen Růžička; Petr Kaňovský; Ivan Rektor; Tomáš Pavlík; Leona Uhlířová; Jaroslav Vydlák
Journal:  J Neural Transm (Vienna)       Date:  2011-07-17       Impact factor: 3.575

4.  Motor and Non-Motor Symptoms in Parkinson's Disease: Effects on Quality of Life.

Authors:  Elif Gökçal; Veysel Eren Gür; Rabia Selvitop; Gülsen Babacan Yildiz; Talip Asil
Journal:  Noro Psikiyatr Ars       Date:  2016-11-11       Impact factor: 1.339

Review 5.  Parkinson disease: an update.

Authors:  Steven J Frucht
Journal:  Neurologist       Date:  2004-07       Impact factor: 1.398

6.  Environmental exposure to manganese in air: Tremor, motor and cognitive symptom profiles.

Authors:  E S Kornblith; S L Casey; D T Lobdell; M A Colledge; R M Bowler
Journal:  Neurotoxicology       Date:  2017-09-28       Impact factor: 4.294

7.  Neurologists' diagnostic accuracy of depression and cognitive problems in patients with parkinsonism.

Authors:  Angela E P Bouwmans; Wim E J Weber
Journal:  BMC Neurol       Date:  2012-06-15       Impact factor: 2.474

8.  Dysautonomia Differentially Influences the Effect of Affective Pain Perception on Quality of Life in Parkinson's Disease Patients.

Authors:  D Rada; J Seco; E Echevarría; B Tijero; L C Abecia; J C Gómez-Esteban
Journal:  Parkinsons Dis       Date:  2016-04-28

9.  Influences of Chronic Mild Stress Exposure on Motor, Non-Motor Impairments and Neurochemical Variables in Specific Brain Areas of MPTP/Probenecid Induced Neurotoxicity in Mice.

Authors:  Udaiyappan Janakiraman; Thamilarasan Manivasagam; Arokiasamy Justin Thenmozhi; Musthafa Mohamed Essa; Rajamani Barathidasan; Chidambaram SaravanaBabu; Gilles J Guillemin; Mohammed A S Khan
Journal:  PLoS One       Date:  2016-01-14       Impact factor: 3.240

10.  In utero and lactational exposure to low-doses of the pyrethroid insecticide cypermethrin leads to neurodevelopmental defects in male mice-An ethological and transcriptomic study.

Authors:  Anthony Laugeray; Ameziane Herzine; Olivier Perche; Olivier Richard; Céline Montecot-Dubourg; Arnaud Menuet; Séverine Mazaud-Guittot; Laurianne Lesné; Bernard Jegou; Stéphane Mortaud
Journal:  PLoS One       Date:  2017-10-11       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.